# Century Therapeutics to Participate in Upcoming Investor Conferences in March
Canonical URL: https://biopharmsignal.com/news/IPSC/century-therapeutics-to-participate-in-upcoming-investor-conferences-in-march-7a741c07
Ticker: IPSC
Company: Century Therapeutics
Source: Century Therapeutics
Published: 2026-02-25 13:00 EST
## Summary

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced...

## Article Body
Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March:

TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA.

Leerink Partners Global Healthcare Conference: Fireside chat at 4:20 p.m. ET on Tuesday, March 10, 2026, in Miami, FL.

A live webcast of the presentations will be available on the Investors page of Century’s website at www.centurytx.com . Archived replays will be available for at least 30 days.

About Century Therapeutics Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

For More Information:

Century Therapeutics Douglas Carr Senior Vice President, Finance investor.relations@centurytx.com

JPA Health Sarah McCabe smccabe@jpa.com
## Recent Company News
- 2026-07-09 12:00 EST — [Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentations-of-cnty-813-preclinical-dat-b81a8a73) — Source: Century Therapeutics
- 2026-06-08 20:05 EST — [New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026](https://biopharmsignal.com/news/IPSC/new-cnty-813-preclinical-data-demonstrate-durable-glucose-control-immune-evasion-e65eb4fc) — Source: Century Therapeutics
- 2026-05-13 12:00 EST — [Century Therapeutics Reports First Quarter Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-first-quarter-financial-results-and-business-update-c4d76676) — Source: Century Therapeutics
- 2026-04-30 20:05 EST — [Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentation-of-cnty-813-preclinical-data-0932a2d5) — Source: Century Therapeutics
- 2026-03-12 12:00 EST — [Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-full-year-2025-financial-results-and-business-updat-7b62a847) — Source: Century Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)